Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hongye Ren
Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China
PLoS ONE
Multidisciplinary
Related publications
Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn140 - Cost-Effectiveness Analysis of Alectinib vs Crizotinib in First Line Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer
Lung Cancer: Targets and Therapy
Oncology
Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy
BMJ Open
Medicine
Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer
Current Oncology
Oncology
P2.13-07 CUX1-ALK: A Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
